Description

Book Synopsis
The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDAs data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities.

FDA's Expedited Drug Programs: Analysis,

    Product form

    A Paperback / softback by Gary Lawrence

    £92.79

    Includes FREE delivery

    RRP £115.99 – you save £23.20 (20%)

    Order before 4pm today for delivery by Wed 9 Sep 2026.

    1 in stock

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of FDA's Expedited Drug Programs: Analysis, by Gary Lawrence

      Book details

      Publisher Nova Science Publishers Inc
      Published 1 September 2016
      ISBN-13 9781634857727
      978-1634857727
      ISBN-10 1634857720
      Also in:
      Pharmacology

      Description

      Book Synopsis
      The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDAs data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities.

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account